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Purpose: To retrospectively identify target recall rates for screening




The study group included 1 872 687 subsequent and
171 104 first screening mammograms from 1996 to 2001
from 172 and 139 facilities, respectively, in six sites of the
Breast Cancer Surveillance Consortium. Institutional re-
view board (IRB) approval was obtained from each site.
Informed consent requirements of the IRBs were followed.
The study was HIPAA compliant. Recall rate was defined
as the percentage of screening studies for which further
work-up was recommended by the radiologist. Sensitivity
was defined as the proportion of cancers that were de-
tected at screening mammography. Piecewise linear re-
gression was used to model sensitivity as a function of
recall rate. This model allows detection of critical recall
rates in which significant changes (shifts) occurred in the
rates that sensitivity increased with increasing recall rate.
Rates were interpreted as number of additional work-ups
per additional cancer detected (AW/ACD) or, in other
words, the estimated number of additional women needed
to be recalled at a given rate to detect one additional
cancer.
Results: For first mammograms, a single shift in the estimated
AW/ACD rate occurred at a recall rate of 10.0%, with the
rate jumping dramatically from 35 to 172. For subsequent
mammograms, four shifts were identified. At a recall rate
of 6.7%, the estimated AW/ACD increased from 80 to
132, which rendered it the highest desirable target recall
rate. At a recall rate of 12.3%, the estimated AW/ACD
was 304, which suggests little benefit for any higher recall
rate.
Conclusion: Recall rates of 10.0% for first and 6.7% for subsequent
mammograms are recommended targets on the basis of
their AW/ACD rates (less than 100).
 RSNA, 2007
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Considerable variation in recall ratesexists between different mammog-raphers, practices, and countries
(1–4). Whereas some variation may be
because of differences among the popula-
tions being screened and the ability of the
radiologist, much is almost certainly be-
cause of variation in radiologist prefer-
ence with regard to the importance of
finding every cancer (reflected in their
sensitivity) and tolerance of false-positive
findings at examinations (reflected in
their specificity and positive predictive
value [PPV]). The recall rate in a facility
is defined as the percentage of screening
studies for which further work-up is
recommended. Recall rates in screening
programs and facilities have been re-
ported to range from less than 1% to
about 15% for screening mammography
(1,5). Across screening programs, re-
call rate has been shown to be positively
correlated with sensitivity and nega-
tively correlated with PPV (1,5). Thus,
use of a lower recall rate places a
greater emphasis on maintaining a high
PPV, while use of a higher recall rate
places greater value on achieving high
sensitivity.
Different groups have recommended
different target recall rates. European
guidelines recommend a target recall
rate of 5%, with an acceptable rate of
less than 7% for first screenings and a
target recall rate of 3% (acceptable rate
5%) for subsequent screenings (6,7).
The American College of Radiology and
the U.S. Agency for Health Care Policy
and Research both recommend an over-
all recall rate of less than 10% (8,9).
However, to our knowledge, these tar-
gets have not been evaluated relative to
their effect on sensitivity and PPV on
the basis of data that reflect current
mammographic screening examinations
within clinical practice in the United
States.
Thus, the goal of our study was to
retrospectively identify target recall rates
for screening mammography on the ba-




The study group included all screening
mammograms from 1996 to 2001 from
six sites of the Breast Cancer Surveil-
lance Consortium (BCSC) from which
data from individual facilities were avail-
able. The BCSC is a consortium of mam-
mographic facilities funded by the Na-
tional Institutes of Health for the purpose
of evaluating the performance of mam-
mography in the community setting (10)
and represents a diverse U.S. population
(11). Seven community-based mammo-
graphic registries located in Vermont,
New Hampshire, North Carolina, Colo-
rado, New Mexico, California, and the
state of Washington have created mam-
mographic databases that link with pop-
ulation-based cancer databases. Each
registry and the Statistical Coordinating
Center (SCC) of the BCSC has received
a federal certificate of confidentiality
and approval from each institution’s re-
view board for the protection of human
subjects to collect and send data (12) to
the SCC and to conduct research with
these data. Three of seven sites were
granted a waiver of informed consent.
At three of the other sites, women had
the option to exclude their data from
research. At one site, the patient’s sig-
nature was required to allow inclusion
of data for research. This study was
Health Insurance Portability and Ac-
countability Act compliant.
For our study, data from one site
were not included because that site did
not collect data at the facility where
mammography was performed.
All data related to the screening
mammographic examination were col-
lected at the facility at the time of mam-
mography. At mammography, patients
completed a breast health survey, which
included date of birth, history and date
of previous mammography, and reported
presence of breast signs and symptoms
(lump, nipple discharge, or others, not
including breast pain).
The interpreting radiologist recorded
the indication for the examination, addi-
tional imaging studies performed, and
date of previous mammography. In addi-
tion, breast density and mammographic
assessment were recorded by using the
recommended categories of the Ameri-
can College of Radiology Breast Imaging
Reporting and Data System (BI-RADS)
(13). Breast density was categorized as
extremely dense, heterogeneously dense,
scattered fibroglandular densities, or al-
most entirely fat. Mammographic as-
sessment was performed with the fol-
lowing categories: 0, needs additional
imaging evaluation; 1, negative finding;
2, benign finding; 3, probably benign
finding; 4, suspicious abnormality; and
5, highly suggestive of malignancy.
The registries collected breast can-
cer information from regional Surveil-
lance, Epidemiology, and End Results
programs, state cancer registries, and
pathology databases. Cancers were cat-
egorized as either invasive disease or
ductal carcinoma in situ. (Lobular carci-






AW/ACD  additional work-ups per additional cancer
detected
BCSC  Breast Cancer Surveillance Consortium
BI-RADS  Breast Imaging Reporting and Data System
PPV  positive predictive value
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Advances in Knowledge
 Evidence-based target recall rates
for screening mammography are
given by using the concept of ad-
ditional work-ups per additional
cancers detected.
 Advanced statistical modeling of
the regression relationship (a con-
cave, monotone, piecewise linear
fit) between sensitivity and recall
rates for screening mammography
is provided.
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Mammograms were separated into
first or subsequent examinations; 4.4%
of the mammograms were dropped at
this point, because it could not be deter-
mined to which group they belonged.
For the subsequent mammograms, 23
(11.8%) of 195 facilities were excluded
from the analysis. Reasons for exclusion
were that 22 facilities had no cancer
results (1993 mammograms) and one
facility had a recall rate greater than
40% (6111 mammograms). For first
mammograms, 50 (26.5%) of 189 facil-
ities were excluded from the analysis.
Reasons for exclusion were that 44
(88%) of the 50 facilities had no cancer
results (7999 mammograms), five (10%)
of 50 facilities had fewer than 100 mam-
mograms (313 mammograms), and one
facility had a recall rate greater than 40%
(429 mammograms). After the exclu-
sions, 1 872 687 subsequent mammo-
grams from 172 facilities and 171 104
first mammograms from 139 facilities re-
mained in the study for analysis. Overall,
findings from 2 043 791 screening mam-
mograms obtained by 912 radiologists
in 172 facilities were included in this
study. This represents an average of
2241 mammograms per radiologist.
Mammographic Assessment
All mammographic studies were as-
sessed by radiologists with BI-RADS
assessments. The follow-up period for
all screening mammography was 12
months or the time to the next screen-
ing examination, if that occurred be-
tween 9 and 12 months later. For our
sensitivity calculations, a screening mam-
mographic examination was considered
to yield a positive finding if the assess-
ment was needs further evaluation, suspi-
cious abnormality, suspicious for malig-
nancy (BI-RADS categories 0, 4, and 5,
respectively), or probably benign (cate-
gory 3) when accompanied by a recom-
mendation for immediate imaging fol-
low-up. A screening mammographic ex-
amination was considered to yield a
negative finding if the assessment was
normal, benign (BI-RADS categories 1
and 2, respectively), or probably benign
(BI-RADS category 3) and did not have
a recommendation for immediate fol-
low-up.
Reference Standard
A mammogram with a positive finding
yielded a true-positive finding (TP) if
cancer was diagnosed and a false-posi-
tive finding (FP) if cancer was not diag-
nosed in the follow-up period. A mam-
mogram with a negative finding yielded
a true-negative finding (TN) if no breast
cancer was diagnosed and a false-nega-
tive finding (FN) if cancer was diag-
nosed in the follow-up period.
Sensitivity was defined as the pro-
portion of cancers that were detected,
calculated as TP/(TP  FN). Specificity
was defined as the proportion of individ-
uals without cancer correctly classified
as having a negative finding at mammog-
raphy, calculated as TN/(TN  FP). Re-
call rate was defined as the proportion
of individuals recalled for additional
work-up, calculated as (TP  FP)/(TP 
FP  TN  FN). Cancer incidence per
1000 mammograms was calculated as
1000  (TP  FN)/(TP  FP  TN  FN).
Statistical Analysis
Sensitivity increases with recall rate,
but not necessarily linearly. By using a
four-step procedure, a nondecreasing,
monotonic, piecewise linear fit to the
data was constructed for sensitivity as a
function of recall rate on the basis of
facility-level data that were weighted by
the number of cancers. First, isotonic
regression analysis (14) was used to
model sensitivity as a constant for vari-
ous ranges of the recall rate. Isotonic
regression provides the least-squares fit
to the raw data among the class of all
monotonic functions. Second, reduced
monotonic regression (15) (*  .50)
was used to identify the recall rate
groups by combining isotonic regression
level sets with similar sensitivity mea-
sures. Third, the reduced monotonic re-
gression model was adjusted for site,
mean age of women, and percentage of
long-interval mammographic examina-
tions (defined for subsequent mammo-
grams as the percentage of mammo-
grams at the facility whose previous
mammograms were more than 27
months earlier). Breast density and per-
centage of women with a personal his-
tory of breast biopsy were not included
in these adjustments because of incom-
plete and/or inconsistent reporting across
the facilities. Fourth, a concave, mono-
tone, piecewise linear fit (called “concave
fit” henceforth) was obtained by joining
the mean recall rates for the adjusted sen-
sitivities of the recall rate groups. A piece-
wise linear segment was used to span
multiple groups, if a nonincreasing slope
with increasing recall (the concavity re-
quirement) was needed. Separate fits
were obtained for first and subsequent
mammograms.
We provide a brief explanation of
the four-step modeling procedure as fol-
lows. Because of random variation, vir-
tually no regression relationships are
perfectly ordered. In our case, sensitiv-
ity does not perfectly increase with in-
creasing recall rate. The recall rate
groups provide regions of the domain
(recall rate in our case) where the re-
sponse (sensitivity in our case) is found
to be fairly constant. Because we do not
believe that sensitivity is intrinsically
flat, with jump points at certain recall
rates, we use the recall rate groups to
construct the concave fit by using linear
interpolation of points.
The slopes for the piecewise linear
segments were interpreted as number
of additional work-ups per additional
cancer detected (AW/ACD). We de-
fined AW/ACD as (DNR)/(DCD), where
DNR is difference in number of patients
recalled and DCD is difference in num-
ber of cancers detected. DCD 
OCR  DS, where OCR is the overall can-
cer rate and DS is difference in sensitiv-
ities. OCR is the number of cancers per
mammogram for the entire study. This
statistic is the reciprocal of what could
be called the “incremental PPV” (ie,
ACD/AW), where the incremental PPV
is obtained by including only women
who would not have been recalled at the
lower recall rate.
The 95% confidence interval for
AW/ACD was obtained by substituting
in the lower and upper 95% confidence
limits for DS in the AW/ACD formula.
The limits were obtained by adding and
subtracting 1.96 times the standard de-
viation for DS, where standard devia-
tion was obtained by using standard
binomial theory. For example, the
variance for the difference in sensitiv-
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ity between recall rate groups 3 and 4
for subsequent mammograms (Table
1) is 0.691  (1  0.691)/1019 
0.749  (1  0.749)/4486  0.000251,
so the 95% confidence interval for DS is
0.749  0.691  1.96  0.0000251 
(0.027, 0.089).
All analyses were performed by an
author (M.J.S.), by incorporating model-
ing suggestions by the authors with pri-
mary mammographic expertise (B.C.Y.,
R.B., R.D.R., R.S.); technical consulta-
tion and review was provided by the
other two statisticians (W.E.B., B.F.Q.).
Statistical software (SAS, version 8.2;
SAS Institute, Cary, NC) was used for
all analyses.
Results
Overall, 171 104 first and 1 872 687 sub-
sequent mammograms obtained at 172
facilities from six BCSC sites were in-
cluded. Performance measures for the
study population were stratified by using
demographic characteristics (Table 2).
For subsequent mammograms, the mean
recall rate was 8.1%, with a sensitivity of
78.2% and a PPV of 5.0%. The overall
cancer rate was 5.15 cancers per 1000
mammograms (9650/1 872 687). For
first mammograms, the recall rate was
13.2%, with a sensitivity of 85.9% and a
PPV of 3.5%. The overall cancer rate
was 5.32 cancers per 1000 mammo-
grams (910/171 104). Sensitivity and
PPV generally increased with increasing
patient age for both first and subsequent
mammograms. While the recall rate
predominantly decreased with increasing
patient age for subsequent mammo-
grams, it increased from the younger
than 40 years age group to the 50–59
years age group before decreasing for
first mammograms.
Subsequent Mammograms
The association between sensitivity and
recall rate for subsequent screening
mammography was modeled by using a
concave fit (Fig 1), which was con-
structed by using the seven recall rate
groups obtained from the reduced mono-
tonic regression fit (Table 1). For exam-
ple, in the third recall rate group, 1019
women from 30 facilities had breast
cancer at the follow-up period, with a
mean recall rate of 4.3% (range, 3.2%–
5.2%) and a sensitivity of 69.1%.
As the recall rate increases, so does
the AW/ACD value (Fig 2). For exam-
ple, increasing recall rate from 1.1% to
2.5% would require an estimated 29 ad-
ditional work-ups to find one additional
cancer, compared with 51 for increas-
ing recall rates from 2.5% to 4.3%. The
two groups with the lowest mean recall
rates (1.1% and 2.5%) represent only
six facilities and less than 4% of mam-
mographic examinations performed.
Thus, the two groups represent recall
rates that most mammographers find
to be unacceptably low. The shift from
group 3 to group 4 is associated with
an estimated AW/ACD of 80; 84.1%
of screening mammograms were eval-
uated at facilities at or beyond recall
rate group 4. Group 4, with recall
rates between 5.3% and 9.2%, was
the largest, representing 75 facilities
that performed 47.8% of all subsequent
mammograms. Recall rate groups 5 and
6 (range, 9.3%–13.6%) were associ-
ated with a single shift of AW/ACD of
132, due to the concavity requirement;
29.8% of mammograms were screened
at these recall rates. An additional
6.5% of mammograms were screened
at recall rates higher than 14%, asso-
ciated with a very high AW/ACD of
304.
Recall rate group 4, with a mean
recall rate of 6.7%, represents the best
choice for mammographers who wish to
maximize their sensitivity while keeping
the estimated AW/ACD less than 100.
Group 4 facilities accounted for 47.8%
of mammograms evaluated, with 15.9%
and 36.3% of women being screened at
facilities with lower and higher recall
rates, respectively (Table 1). Estimated
performance measures for recall rates
ranging from 3% to 12% were obtained
from the concave fit (Table 3); this in-
formation might be useful to mammog-
raphers contemplating shifts in their in-
dividual recall rates.
First Mammograms
The association between sensitivity and
recall rate for first screening mammog-
raphy was modeled with a concave fit,
which had a single shift in AW/ACD
estimates (Fig 3), on the basis of four
Table 1
Association between Recall Rate and Sensitivity for Subsequent Mammographic Screenings
Recall Rate Group No. of Facilities No. of Mammograms* No. of Cancers
Recall Rate (%)
Sensitivity† Cancer Detection Rate‡Range Mean
1 3 26 903 (1.4) 110 0.3–1.5 1.1 53.0 2.73
2 3 45 922 (2.5) 230 2.3–3.1 2.5 62.3 3.21
3 30 224 844 (12.0) 1019 3.2–5.2 4.3 69.1 3.56
4 75 894 982 (47.8) 4486 5.3–9.2 6.7 74.9 3.86
5 27 337 221 (18.0) 1742 9.3–11.5 10.2 78.5 4.04
6 20 220 362 (11.8) 1260 11.6–13.6 12.3 83.0 4.27
7 14 122 453 (6.5) 803 14.0–20.4 15.4 85.0 4.38
Overall 172 1 872 687 (100) 9650 0.3–20.4 8.1 78.2 4.03
* Data in parentheses are percentages.
† Adjusted for site, mean age of woman, and percentage of long-interval mammograms.
‡ Number of cancers detected per 1000 mammograms, assuming 5.15 cancers per 1000 mammograms, which was the rate observed in our study for subsequent screenings.
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recall rate groups (Table 4). Recall rate
group 2 had the greatest number of
mammograms, at 53.7%, and a recall
rate range of 6.1%–13.2%, with an
average of 10%. Recall rate group 3,
with recall rates ranging from 13.3%
to 23.1%, reflects the practices where
40.4% of mammograms were evalu-
ated. Recall rate groups 1 and 4 repre-
sent exceptionally low (2.4%–6.0%)
and high (23.2%–27.9%) practice pat-
terns, seen in a total of 10 practices
(5.9% of patients).
These four recall rate groups give
rise to a single shift in AW/ACD. Below
10%, the estimated value was 35, com-
pared with 172 for higher recall rates.
Thus, a target recall of 10% is the best
choice for mammographers who wish to
maximize their sensitivity while keeping
the estimated AW/ACD below either 50
or 100 (Fig 4). Group 2 facilities, whose
recall rates include the target rate of
10%, accounted for 53.7% of cancers
detected, with 3.4% and 42.9% of
women being screened at facilities with
lower and higher recall rates, respec-
tively (Table 4).
Discussion
For a given mammographer, sensitivity
clearly increases with recall rate, be-
cause recalling additional women from a
given cohort could not decrease the
true-positive rate. Indeed, if all women
were recalled, very few cancers would
be missed. Consequently, establishing a
target recall rate should not be based on
Table 2
Performance according to Demographic Characteristics
Characteristic
























40 46 987 (2.5) 9.0 68.2 1.4 88 60 472 (35.3) 11.2 71.3 1.4 129
40–49 545 684 (29.1) 9.2 70.7 2.3 1640 70 634 (41.3) 14.3 82.1 2.0 240
50–59 574 505 (30.7) 8.3 78.1 4.5 2779 18 068 (10.6) 15.6 92.1 4.9 151
60–69 367 301 (19.6) 7.4 79.7 7.0 2381 11 245 (6.6) 13.5 89.3 8.9 150
70 338 210 (18.1) 6.6 81.9 10.2 2762 10 685 (6.2) 12.4 91.7 16.6 240
Race
Black 107 722 (5.8) 6.4 77.3 5.4 484 17 754 (10.4) 12.6 80.8 4.5 125
White 1 267 170 (67.7) 8.1 78.1 5.1 6648 105 085 (61.4) 13.2 85.2 3.2 520
Other 111 280 (5.9) 6.7 80.7 5.3 483 18 684 (10.9) 10.9 88.3 4.1 94
Unknown 386 515 (20.6) 8.9 78.2 4.6 2035 29 581 (17.3) 14.9 90.6 3.5 171
Family history of breast cancer
Yes 245 660 (13.1) 8.8 76.8 6.0 1689 12 556 (7.3) 14.7 86.9 4.0 84
No 1 343 531 (71.7) 8.6 80.0 4.6 6615 135 166 (79.0) 13.7 87.3 3.3 691
Unknown 283 496 (15.1) 5.1 71.5 6.6 1346 23 382 (13.7) 9.2 78.5 4.9 135
History of breast biopsy or surgery
Yes 341 606 (18.2) 10.3 75.7 5.1 2372 6097 (3.6) 17.3 79.2 3.6 48
No 1 383 100 (73.9) 7.7 79.3 4.9 6494 154 381 (90.2) 13.1 85.4 3.3 785
Unknown 147 981 (7.9) 7.0 76.9 5.8 784 10 626 (6.2) 11.7 96.1 5.9 77
Current breast problem
Yes 27 974 (1.5) 16.9 76.1 6.5 402 6513 (3.8) 22.4 88.6 7.5 123
No 1 362 689 (72.8) 8.1 78.0 4.7 6592 120 755 (70.6) 12.5 84.8 3.0 545
Unknown 482 024 (25.8) 7.6 79.2 5.7 2656 43 836 (25.6) 13.5 87.2 3.5 242
Time since last mammography (m)
27 1 414 723 (75.5) 7.5 76.3 5.0 6937
27 302 470 (16.2) 9.6 83.9 5.1 1785
Unknown 155 494 (8.3) 10.6 81.6 4.6 928
Parenchymal density
Extremely dense 112 195 (6.0) 9.9 64.1 3.6 618 14 499 (8.5) 11.8 70.5 2.5 61
Heterogeneously dense 572 461 (30.6) 9.5 75.3 4.6 3311 55 869 (32.7) 14.0 81.6 2.8 267
Scattered fibroglandular densities 686 148 (36.6) 7.2 82.4 5.5 3304 58 288 (34.1) 13.3 90.3 4.4 373
Almost entirely fat 129 132 (6.9) 3.9 89.1 6.4 357 10 393 (6.1) 8.6 88.5 5.2 52
Unknown 372 751 (19.9) 8.4 78.6 5.1 2060 32 055 (18.8) 13.5 87.9 3.1 157
Overall 1 872 687 (100.0) 8.1 78.2 5.0 9650 171 104 (100.0) 13.2 85.9 3.5 910
* Data in parentheses are percentages.
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maximizing sensitivity alone. Judgment
is needed to settle on a recall rate at
which the additional yield of cancers de-
tected is not worth the additional num-
ber of recalls. Such a decision is diffi-
cult, because it represents a trade-off
between the benefit of finding additional
cancers and the increased number of
procedures for noncancers and the as-
sociated anxiety and monetary cost that
women experience as they undergo fur-
ther work-ups (16–18). It seems rea-
sonable that values of AW/ACD should
be below the prevailing cancer rate.
We believe that the best choices for
recall rate targets are those that repre-
sent the mean recall rates for one of the
recall rate groups established in the Re-
sults section. By using the metric of
AW/ACD, a detriment (additional work-
up) to benefit measure of increasing or
decreasing recall rate, individual mam-
mographers may be able to gauge the
effect that changing their recall rate by
1% would have on performance.
While individual mammographers
and informed patients may have differ-
ent ideas regarding the optimal trade-
off, we suggest using an AW/ACD of, at
most, 100. This benchmark level seems
to be a good choice. In our study, a level
larger than 132 would lead to a target
recall rate of 12.3%, which is higher
than that recommended by American
Figures 1, 2
Figure 1: Graph of sensitivity as function of recall rate for subsequent screen-
ings at 172 facilities, with concave (solid curved line) and reduced monotonic
regression (step function) fits. Size of circles depicts relative number of cancers
from each facility. (Data from three facilities with sensitivities less than 50% are
not shown.) Dashed lines show where the piecewise linear fit obtained by joining
mean recall rates of adjacent groups differs from concave fit. E  individual facil-
ity (weighted by number of cancers from that facility).
Figure 2: Graph of concave fit for subsequent screenings. Vertical dashed lines
show where model changes slope. Corresponding estimated AW/ACD values are
shown (represented as base of triangle for a fixed gain in sensitivity), along with
95% confidence intervals.
Table 3






Cancers Detected* PPV† AW/ACD‡
Incremental
PPV§
3 64.1 9.1 .110 . . . . . .
4 67.9 11.4 .087 51 .020
5 70.7 13.7 .073 68 .015
6 73.1 15.9 .063 82 .012
7 75.3 18.0 .055 94 .011
8 76.8 20.2 .049 132 .008
9 78.2 22.3 .045 132 .008
10 79.7 24.4 .041 132 .008
11 81.1 26.3 .038 132 .008
12 82.6 28.2 .035 132 .008
* Work-ups per cancers detected  recall rate/(5.15/1000 	 sensitivity), assuming 5.15 cancers/1000 mammograms.
† PPV  cancers detected per work-up.
‡ AW/ACD  (difference in number of patients recalled)/(difference in number of cancers detected), where the difference is
with the previous row.
§ Incremental PPV  ACD/AW.
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College of Radiology guidelines (8,9). A
level below 80 would result in a target
recall rate of 4.3%. The latter rate is
close to European guidelines (6,7),
which call for rates below 5%. How-
ever, less than 15% of U.S. patients
underwent mammography at facilities
with rates at or below that rate. The
resulting target recall rates are 10.0%
for first mammograms and 6.7% for
subsequent mammograms. Notably, the
recall rate groups with the largest per-
centages of mammograms evaluated in-
clude these target rates, with a small
percentage below these rates and a
sizable percentage above—42.9% of
first and 36.3% of subsequent mam-
mograms. European guidelines of less
than 5% for subsequent screenings
correspond to a lower tolerance for
AW/ACD (6,7). Interpreted according
to our concave fit, their recommenda-
tions would suggest use of a maximum
AW/ACD between 51 and 80, which
would lead to a recall rate group with a
4.3% mean recall rate and 69% sensi-
tivity. Their guideline for less than 7%
recalls after first screenings would place
them in the lower end of the 6.1%–
13.2% recall rate group given in Table
Figures 3, 4
Figure 3: Graph of sensitivity as function of recall rate for first screenings at
139 facilities, with concave (solid curved line) and reduced monotonic regression
(step function) fits. Size of circles depicts relative number of cancers from each
facility. (Data from six facilities with sensitivities less than 50% are not shown.)
Dashed lines show where the piecewise linear fit obtained by joining mean recall
rates of adjacent groups differs from concave fit. E  individual facility (weighted
by number of cancers from that facility).
Figure 4: Graph of concave fit for first screenings. Vertical dashed lines show
where model changes slope. Corresponding estimated AW/ACD values are shown
(represented as base of triangle for a fixed gain in sensitivity), along with 95%
confidence intervals.
Table 4
Association between Recall Rate and Sensitivity for First Mammographic Screenings
Recall Rate Group No. of Facilities No. of Mammograms* No. of Cancers
Recall Rate (%)
Sensitivity† Cancer Detection Rate‡Range Mean
1 4 5876 (3.4) 31 2.4–6.0 4.7 55.2 2.96
2 67 91 921 (53.7) 471 6.1–13.2 10.0 83.3 4.47
3 62 69 108 (40.4) 383 13.3–23.1 17.4 87.8 4.71
4 6 4199 (2.5) 25 23.2–27.9 25.1 100.0 5.37
Overall 139 171 104 (100) 910 2.4–27.9 13.1 85.9 4.61
* Data in parentheses are percentages.
† Adjusted for site and mean age of woman.
‡ Number of cancers detected per 1000 mammograms, assuming 5.32 cancers per 1000 mammograms, which was the rate observed in our study for first screenings.
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4, which corresponds to an 83.3% sen-
sitivity.
Yankaskas et al (19) showed that
these differences do exist when compar-
ing international screening recall rates.
In a meta-analysis of 24 mammographic
screening programs, Elmore et al (1) con-
cluded that “the percentage of mammo-
grams judged to be abnormal in North
American programs was 2–4 percentage
points higher than it was in programs
from other countries without evident ben-
efit in the yield of cancers detected per
1000 women screened, although an in-
crease was noted in DCIS [ductal carci-
noma in situ] detection.” This may be ex-
aggerated because they included BI-
RADS category 3 as a recall, which is not
done internationally or in this study.
Yankaskas et al (5) concluded that
facilities with recall rates between 4.9%
and 5.5% achieved the best trade-off of
sensitivity and PPV. Their range of re-
call rates was obtained by performing
reduced monotonic regressions on the
relationships of sensitivity and PPV with
recall rate and by identifying the range
in which both sensitivity and PPV were
maintained at high levels. Our study is
nearly 10 times larger than theirs and,
to our knowledge, is the largest study to
date to examine this issue in the United
States. We believe that it improves on
that study by splitting mammograms
into first and subsequent screenings and
by using the concave fit approach, with
its accompanying AW/ACD concept.
Their target rate is between the reason-
able targets of 4.3% and 6.7% pre-
sented by us.
There is some concern about the
establishment of recall rate guidelines in
mammography. Gur et al (20) examined
the correlation between recall and can-
cer detection rates in a group of 10 radi-
ologists from a single academic institu-
tion. Noting an increase in the pre-
sumed linear relationship, where the
recall rates ranged from 7.7% to
17.2%, they concluded that “the perfor-
mance level of a radiologist in the
screening environment is a complex,
multifactorial issue that cannot and
should not be simplified. Reducing recall
rates by “decree” (through the enforce-
ment of recommended practice guide-
lines) may result in a corresponding re-
duction in the detection rates.” Their
study results, however, focused on de-
tection rates, which lack the additional
information on missed cancers that is
available with sensitivity. They also
modeled the relationship between the
recall and detection rates as linear.
Consequently, their evidence cannot
suggest that any level of recall rate is too
high. Inspection of their data suggests
that beyond about a 12% recall rate,
little or no gain in the detection rate
occurred. In a recent commentary,
Hardesty et al (21) suggested usage of
three nonlinear models to determine
the sensitivity–recall rate relationship,
including a concave fit, which they erro-
neously called convex. We used a con-
cave fit in our analysis, which we believe
makes sense clinically because discrimi-
nation between cancer and noncancer
as the recall rate increases becomes in-
creasingly difficult.
In a re-review of missed cancers
from a Dutch breast screening program
that has the lowest recall rate world-
wide, Otten et al (22) examined the
effect of increasing the recall rate. In
their article, 15 mammographers re-
reviewed 495 screening mammograms
with negative findings for subsequent
screenings, which included 245 missed
cancers, from which they extrapolated
their outcome measures to 500 000 sub-
sequent screenings by using an equiva-
lent concept to AW/ACD. For recall
rates between 4% and 7%, their AW/
ACD values were 30%–70% higher than
ours. For recall rates between 8% and
10%, their AW/ACD values were within
14% of ours. It is unclear whether the
higher values they obtained are because
of differences in mammographic evalua-
tion between the United States and the
Netherlands, different screening inter-
vals, or the relatively few cancers on
which they based their estimates.
Our study had limitations. The rela-
tionship between recall rate and sensi-
tivity was assessed by using seven com-
munity-based registries in the United
States. Extension of these results to
other U.S. states and to other regions of
the world cannot be assumed from sta-
tistical principles but must rather be
based on subjective judgment. Because
the women included in the BCSC are
largely representative of women under-
going screening mammography within
the United States, however, we believe
it is likely that most radiologists’ pa-
tients will be similar to those within the
BCSC (11). Sensitivity differences were
found between the states. We believe
that this is most likely because of differ-
ences in completeness in identifying
cancers between the various state regis-
tries. This site difference was adjusted
for in obtaining our models, with North
Carolina as the referent group because
it provided the largest number of mam-
mograms to this study. Thus, the actual
sensitivities will differ by state. How-
ever, the locations where the AW/ACD
rates shifted were modeled as being the
same for all sites. As further data are
accrued, additional covariates affecting
the sensitivities or, perhaps, the loca-
tion of AW/ACD rate shifts may be
found. However, to our knowledge, this
study represents the largest collective
evidence on the recall rate–sensitivity
relationship published to date and in-
corporates the data from the second-
largest study (5).
The data and analysis presented
demonstrate a wide variation in recall
rate–sensitivity pairs in this conve-
nience sample of U.S. radiologists. This
variation likely represents both differ-
ent preferences and different abilities
among radiologists. Clustering of the fa-
cilities’ results, together with analysis of
the gains from additional work-up for
these radiologists, strongly suggests
ranges of targeted performance. We
recommend operating at a target re-
call rate of approximately 6.7% for
subsequent mammograms and 10.0%
for first mammograms, because these
rates keep the estimated number of
AW/ACD lower than 100.
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